ImmunoGen reports 'mature' data from FORWARD II expansion cohort
ImmunoGen announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin in patients with folate receptor alpha-positive platinum-resistant ovarian cancer. These findings will be presented at the 2019 American Society of Clinical Oncology Annual Meeting, which is being held May 31 - June 4 in Chicago, IL. "We are pleased that the combination of mirvetuximab plus Avastin has generated significant anti-tumor activity in patients with platinum-resistant disease, with trends toward deeper, more durable responses seen in individuals with higher FRalpha expression and a favorable tolerability profile. The outcomes observed in patients with medium or high FRalpha expression are encouraging with respect to those reported in similar patient populations for Avastin plus chemotherapy," said Anna Berkenblit, M.D., Vice President and Chief Medical Officer of ImmunoGen. "Our goal remains to establish mirvetuximab as the combination agent of choice in ovarian cancer, supporting its use in earlier lines of therapy. These mature data support further exploration of this doublet, as well as the ongoing expansion study evaluating a triplet combination of mirvetuximab with Avastin and carboplatin in patients with platinum-sensitive disease."